Adelphi Trust’s Quest Diagnostics DGX Stock Holding History

Adelphi Trust’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$261K	Buy	1,230 +185	+18%	+$36.3K	0.17%	99
2026 Q1	$205K	Buy	+1,045	New	+$203K	0.17%	103

Other funds holding DGX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

EIG

EdgePoint Investment Group Toronto, Ontario, Canada $13.2B AUM 32.43% 1-Year Est. Return

Adelphi Trust's DGX Position: Q2 2026 in Review

Adelphi Trust increased its Quest Diagnostics (DGX) stake by 18% in Q2 2026, buying an estimated $36.3K and bringing the position to 1,230 shares worth $261K. The position accounts for 0.17% of the portfolio, ranked #99.

Adelphi Trust first reported a position in DGX in Q1 2026 and has held it in 2 quarters since. 1,099 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

Adelphi Trust held 1,230 shares of Quest Diagnostics worth $261K as of Q2 2026.
Adelphi Trust bought 185 Quest Diagnostics shares in Q2 2026, an estimated $36.3K.
Quest Diagnostics made up 0.17% of Adelphi Trust's portfolio in Q2 2026, its #99 holding.
Adelphi Trust first reported a position in Quest Diagnostics in Q1 2026 and has held it in 2 quarters since.
1,099 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Adelphi Trust's 13F filing for Q2 2026, filed 1 Jul 2026.